{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:16:15Z","timestamp":1794798975461,"version":"4.9.1"},"reference-count":74,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Malignant peripheral nerve sheath tumor (MPNST) is a rare, often high-grade sarcoma. A small subset of MPNST shows evidence of heterologous rhabdomyoblastic differentiation, also known as malignant triton tumor (MTT). Immunohistochemical loss of histone 3 lysine 27 trimethylation (H3K27me3) has previously been described as a reliable marker for both MPNST and MTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To assess the loss of H3K27me3 as a potential tool for discriminating MTT from embryonal rhabdomyosarcoma (ERMS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>We studied the immunohistochemical expression of H3K27me3 in 23 pediatric cases of confirmed ERMS. Of the 23 patients, 21 were male and 2 were female, with an age range of 2 months to 18 years (median, 5 years). Most of the tumors arose in the paratesticular soft tissue (n = 14), with other locations including the pelvis (n = 3), thigh (n = 2), abdomen (n = 1), orbit (n = 1), prostate gland (n = 1), and parotid gland (n = 1). All cases had characteristic morphologic features of ERMS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>By immunohistochemistry, all tested cases expressed desmin (18 of 18), myogenin (20 of 20), and MyoD1 (5 of 5). More than half of the cases (12 of 23; 52%) showed loss (nuclear absence) of H3K27me3, defined as staining in less than 5% of the tumor cells. The remaining cases demonstrated some degree of partial staining with H3K27me3, ranging from 5% to 40% of the tumor cells. No significant correlation between H3K27me3 expression and clinicopathologic features was identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>Loss of H3K27me3 frequently occurs in ERMS (52%) and is not reliable in distinguishing ERMS from MTT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2024-0199-oa","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T01:57:41Z","timestamp":1739757461000},"page":"944-949","source":"Crossref","is-referenced-by-count":3,"title":["Loss of H3K27me3 Is Not Specific to Malignant Triton Tumor: Immunohistochemical Analysis of 23 Cases of Embryonal Rhabdomyosarcoma"],"prefix":"10.5858","volume":"149","author":[{"given":"Laura M.","family":"Warmke","sequence":"first","affiliation":[{"name":"From the Department of Pathology, Indiana University School of Medicine, Indianapolis (Warmke, Davis)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Davis","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, Indiana University School of Medicine, Indianapolis (Warmke, Davis)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyaa","family":"Al-Ibraheemi","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Boston Children\u2019s Hospital and Harvard Medical School, Boston, Massachusetts (Al-Ibraheemi)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Arnold","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Children\u2019s Hospital Colorado, Aurora (Arnold)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Tan","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Stanford University, Stanford, California (Tan)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Shenoy","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Nationwide Children\u2019s Hospital and The Ohio State University College of Medicine, Columbus (Shenoy)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea F.","family":"Surrey","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Children\u2019s Hospital of Philadelphia, Philadelphia, Pennsylvania (Surrey)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Parham","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Children\u2019s Hospital of Los Angeles, Los Angeles, California (Parham)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin R.","family":"Rudzinski","sequence":"additional","affiliation":[{"name":"the Department of Pathology, Seattle Children\u2019s Hospital, University of Washington School of Medicine, Seattle (Rudzinski)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","reference":[{"key":"i1543-2165-149-10-944-b01","series-title":"Libman Anniversary","first-page":"793","article-title":"Recklinghausen\u2019s neurofibromatosis, sensory neuromas and motor neuromas","volume":"2","author":"Masson","year":"1932","unstructured":"Masson P. Recklinghausen\u2019s neurofibromatosis, sensory neuromas and motor neuromas. In: Libman Anniversary. Vol 2. New York, NY: International Press; 1932:793\u2013802."},{"issue":"2","key":"i1543-2165-149-10-944-b02","series-title":"Cancer","first-page":"426","article-title":"Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant \u201cTriton\u201d tumors)","volume":"32","author":"Woodruff","year":"1973","unstructured":"Woodruff JM,\nChernik NL,\nSmith MC,\nMillett WB,\nFoote FW Jr. Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant \u201cTriton\u201d tumors). Cancer. 1973;32(2):426\u2013439."},{"key":"i1543-2165-149-10-944-b03","series-title":"C R Assoc Anat","first-page":"279","article-title":"Formation de members surnumeraires","volume":"20","author":"Locatelli","year":"1925","unstructured":"Locatelli P. Formation de members surnumeraires. C R Assoc Anat. 1925;20:279\u2013282."},{"key":"i1543-2165-149-10-944-b04","series-title":"J Pathol","first-page":"151","article-title":"H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumors","volume":"252","author":"Lyskjaer","year":"2020","unstructured":"Lyskjaer I,\nLindsay D,\nTirabosco R, et al. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumors. J Pathol. 2020;252:151\u2013164."},{"issue":"3","key":"i1543-2165-149-10-944-b05","series-title":"Mol Cell","first-page":"437","article-title":"PRC2.1 and PRC2.2 synergize to coordinate H3K27me3 trimethylation","volume":"76","author":"Healy","year":"2019","unstructured":"Healy E,\nMucha M,\nGlancy E, et al. PRC2.1 and PRC2.2 synergize to coordinate H3K27me3 trimethylation. Mol Cell. 2019;76(3):437\u2013452."},{"issue":"1","key":"i1543-2165-149-10-944-b06","series-title":"Mod Pathol","first-page":"4","article-title":"Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics","volume":"29","author":"Schaefer","year":"2016","unstructured":"Schaefer IM,\nFletcher CD,\nHornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29(1):4\u201313."},{"issue":"11","key":"i1543-2165-149-10-944-b07","series-title":"Nat Genet","first-page":"1227","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","unstructured":"Lee W,\nTeckie S,\nWiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227\u20131232."},{"issue":"10","key":"i1543-2165-149-10-944-b08","series-title":"Am J Surg Pathol","first-page":"1323","article-title":"Beyond \u201cTriton\u201d: malignant peripheral nerve sheath tumors with complete heterologous rhabdomyoblastic differentiation mimicking spindle cell rhabdomyosarcoma","volume":"43","author":"Hornick","year":"2019","unstructured":"Hornick JL,\nNielsen GP. Beyond \u201cTriton\u201d: malignant peripheral nerve sheath tumors with complete heterologous rhabdomyoblastic differentiation mimicking spindle cell rhabdomyosarcoma. Am J Surg Pathol. 2019;43(10):1323\u20131330."},{"key":"i1543-2165-149-10-944-b09","series-title":"Ann Diagn Pathol","first-page":"151735","article-title":"Loss of H3K27me3 occurs in a large subset of embryonal rhabdomyosarcomas: immunohistochemical and molecular analysis of 25 cases","volume":"52","author":"Tomassen","year":"2021","unstructured":"Tomassen T,\nKester LA,\nTops BB, et al. Loss of H3K27me3 occurs in a large subset of embryonal rhabdomyosarcomas: immunohistochemical and molecular analysis of 25 cases. Ann Diagn Pathol. 2021;52:151735."},{"issue":"6","key":"i1543-2165-149-10-944-b10","series-title":"Virchows Arch","first-page":"1233","article-title":"Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation","volume":"479","author":"Ito","year":"2021","unstructured":"Ito Y,\nKohashi K,\nEndo M, et al. Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation. Virchows Arch. 2021;479(6):1233\u20131244."},{"key":"i1543-2165-149-10-944-b11","series-title":"Ann Diagn Pathol","first-page":"151967","article-title":"Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): an immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors","volume":"59","author":"Thangaiah","year":"2022","unstructured":"Thangaiah JJ,\nWestling BE,\nRoden AC, et al. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): an immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. Ann Diagn Pathol. 2022;59:151967."},{"issue":"3","key":"i1543-2165-149-10-944-b12","series-title":"Histopathology","first-page":"385","article-title":"Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumors","volume":"70","author":"Asano","year":"2017","unstructured":"Asano N,\nYoshida A,\nIchikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumors. Histopathology. 2017;70(3):385\u2013393."},{"issue":"3","key":"i1543-2165-149-10-944-b13","series-title":"Mod Pathol","first-page":"435","article-title":"H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features","volume":"32","author":"Makise","year":"2019","unstructured":"Makise N,\nSekimizu M,\nKonishi E, et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod Pathol. 2019;32(3):435\u2013445."},{"issue":"12","key":"i1543-2165-149-10-944-b14","series-title":"Mod Pathol","first-page":"1677","article-title":"Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions","volume":"30","author":"Le Guellec","year":"2017","unstructured":"Le Guellec S,\nMacagno N,\nVelasco V, et al. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol. 2017;30(12):1677\u20131687."},{"issue":"6","key":"i1543-2165-149-10-944-b15","series-title":"Mod Pathol","first-page":"582","article-title":"Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival","volume":"29","author":"Cleven","year":"2016","unstructured":"Cleven AHG,\nSannaa GAA,\nBriaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29(6):582\u2013590."},{"issue":"1","key":"i1543-2165-149-10-944-b16","series-title":"Brain Tumor Pathol","first-page":"23","article-title":"Reduced H3K27me3 levels in diffuse gliomas: association with 1p\/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors","volume":"38","author":"Kitahama","year":"2021","unstructured":"Kitahama K,\nIijima S,\nSumiishi A, et al. Reduced H3K27me3 levels in diffuse gliomas: association with 1p\/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors. Brain Tumor Pathol. 2021;38(1):23\u201329."},{"issue":"6","key":"i1543-2165-149-10-944-b17","series-title":"Acta Neuropathol","first-page":"955","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","unstructured":"Katz LM,\nHielscher T,\nLiechty B, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018;135(6):955\u2013963."},{"issue":"12","key":"i1543-2165-149-10-944-b18","series-title":"Mod Pathol","first-page":"1710","article-title":"Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors","volume":"30","author":"Pekmezci","year":"2017","unstructured":"Pekmezci M,\nCuevas-Ocampo AK,\nPerry A,\nHorvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017;30(12):1710\u20131719."},{"key":"i1543-2165-149-10-944-b19","series-title":"Am J Surg Pathol","first-page":"656","article-title":"The distinction between malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma: a critical reappraisal of the diagnostic utility of MDM2 and H3K27me3 status","volume":"42","author":"Makise","year":"2018","unstructured":"Makise N,\nSekimizu M,\nKubo T, et al. The distinction between malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma: a critical reappraisal of the diagnostic utility of MDM2 and H3K27me3 status. Am J Surg Pathol. 2018;42:656\u2013664."},{"issue":"2","key":"i1543-2165-149-10-944-b20","series-title":"Histopathology","first-page":"321","article-title":"Radiation-associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation","volume":"78","author":"Panse","year":"2021","unstructured":"Panse G,\nMito JK,\nIngram DR, et al. Radiation-associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation. Histopathology. 2021;78(2):321\u2013326."},{"issue":"5","key":"i1543-2165-149-10-944-b21","series-title":"Mod Pathol","first-page":"640","article-title":"Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation","volume":"35","author":"Ishihara","year":"2022","unstructured":"Ishihara S,\nYamamoto H,\nIwasaki T, et al. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation. Mod Pathol. 2022;35(5):640\u2013648."},{"issue":"6","key":"i1543-2165-149-10-944-b22","series-title":"Genes Chromosomes Cancer","first-page":"397","article-title":"High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis","volume":"50","author":"Paulson","year":"2011","unstructured":"Paulson V,\nChandler G,\nRakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50(6):397\u2013408."},{"issue":"3","key":"i1543-2165-149-10-944-b23","series-title":"Clin Genet","first-page":"341","article-title":"Neurofibromatosis type 1 and malignancy in childhood","volume":"89","author":"Varan","year":"2016","unstructured":"Varan A,\n\u015een H,\nAyd\u0131n B,\nYal\u00e7in B,\nKutluk T,\nAky\u00fcz C. Neurofibromatosis type 1 and malignancy in childhood. Clin Genet. 2016;89(3):341\u2013345."},{"key":"i1543-2165-149-10-944-b24","series-title":"JCO Precis Oncol","first-page":"e2300597","article-title":"NF1-driven rhabdomyosarcoma phenotypes: a comparative clinical and molecular study of NF1-mutant rhabdomyosarcoma and NF1-associated malignant triton tumor","volume":"8","author":"de Traux de Wardin","year":"2024","unstructured":"de Traux de Wardin H,\nDermawan JK,\nVanoli F, et al. NF1-driven rhabdomyosarcoma phenotypes: a comparative clinical and molecular study of NF1-mutant rhabdomyosarcoma and NF1-associated malignant triton tumor. JCO Precis Oncol. 2024;8:e2300597."},{"issue":"3","key":"i1543-2165-149-10-944-b25","series-title":"Genes Chromosomes Cancer","first-page":"310","article-title":"Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes","volume":"33","author":"Bridge","year":"2002","unstructured":"Bridge JA,\nLiu J,\nQualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33(3):310\u2013321."},{"issue":"2","key":"i1543-2165-149-10-944-b26","series-title":"Cancer Discov","first-page":"216","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","unstructured":"Shern JF,\nChen L,\nChmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216\u2013231."},{"issue":"3\u20134","key":"i1543-2165-149-10-944-b27","series-title":"Crit Rev Oncog","first-page":"227","article-title":"Pediatric rhabdomyosarcoma","volume":"20","author":"Shern","year":"2015","unstructured":"Shern JF,\nYohe ME,\nKhan J. Pediatric rhabdomyosarcoma. Crit Rev Oncog. 2015;20(3\u20134):227\u2013243."},{"issue":"3","key":"i1543-2165-149-10-944-b28","series-title":"PLoS Genet","first-page":"e1005075","article-title":"Clonality and evolutionary history of rhabdomyosarcoma","volume":"11","author":"Chen","year":"2015","unstructured":"Chen L,\nShern JF,\nWei JS, et al. Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet. 2015;11(3):e1005075."},{"issue":"26","key":"i1543-2165-149-10-944-b29","series-title":"J Clin Oncol","first-page":"2859","article-title":"Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium","volume":"39","author":"Shern","year":"2021","unstructured":"Shern JF,\nSelfe J,\nIzquierdo E, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium. J Clin Oncol. 2021;39(26):2859\u20132871."},{"issue":"4","key":"i1543-2165-149-10-944-b30","series-title":"Genes Chromosomes Cancer","first-page":"217","article-title":"Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma","volume":"15","author":"Iolascon","year":"1996","unstructured":"Iolascon A,\nFaienza MF,\nCoppola B, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer. 1996;15(4):217\u2013222."},{"issue":"2","key":"i1543-2165-149-10-944-b31","series-title":"Cell","first-page":"265","article-title":"The regulation of INK4\/ARF in cancer and aging","volume":"127","author":"Kim","year":"2006","unstructured":"Kim WY,\nSharpless NE. The regulation of INK4\/ARF in cancer and aging. Cell. 2006;127(2):265\u2013275."},{"issue":"50","key":"i1543-2165-149-10-944-b32","series-title":"Proc Natl Acad Sci U S A","first-page":"20007","article-title":"Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma","volume":"104","author":"Beroukhim","year":"2007","unstructured":"Beroukhim R,\nGetz G,\nNghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104(50):20007\u201320012."},{"issue":"8","key":"i1543-2165-149-10-944-b33","series-title":"Blood","first-page":"4322","article-title":"Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis","volume":"111","author":"Balgobind","year":"2008","unstructured":"Balgobind BV,\nVan Vlierberghe P,\nvan den Ouweland AM, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;111(8):4322\u20134328."},{"issue":"12","key":"i1543-2165-149-10-944-b34","series-title":"Neoplasia","first-page":"1362","article-title":"Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations","volume":"10","author":"Sangha","year":"2008","unstructured":"Sangha N,\nWu R,\nKuick R, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008;10(12):1362\u20131372."},{"issue":"7521","key":"i1543-2165-149-10-944-b35","series-title":"Nature","first-page":"247","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"De Raedt","year":"2014","unstructured":"De Raedt T,\nBeert E,\nPasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514(7521):247\u2013251."},{"issue":"12","key":"i1543-2165-149-10-944-b36","series-title":"Arch Pathol Lab Med","first-page":"1878","article-title":"Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor)","volume":"130","author":"Stasik","year":"2006","unstructured":"Stasik CJ,\nTawfik O. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med. 2006;130(12):1878\u20131881."},{"issue":"1","key":"i1543-2165-149-10-944-b37","series-title":"Clin Epigenetics","first-page":"9","article-title":"Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population","volume":"16","author":"Patrizi","year":"2024","unstructured":"Patrizi S,\nMiele E,\nFalcone L, et al. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population. Clin Epigenetics. 2024;16(1):9."},{"key":"i1543-2165-149-10-944-b01","series-title":"Libman Anniversary","first-page":"793","article-title":"Recklinghausen\u2019s neurofibromatosis, sensory neuromas and motor neuromas","volume":"2","author":"Masson","year":"1932","unstructured":"Masson P. Recklinghausen\u2019s neurofibromatosis, sensory neuromas and motor neuromas. In: Libman Anniversary. Vol 2. New York, NY: International Press; 1932:793\u2013802."},{"issue":"2","key":"i1543-2165-149-10-944-b02","series-title":"Cancer","first-page":"426","article-title":"Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant \u201cTriton\u201d tumors)","volume":"32","author":"Woodruff","year":"1973","unstructured":"Woodruff JM,\nChernik NL,\nSmith MC,\nMillett WB,\nFoote FW Jr. Peripheral nerve tumors with rhabdomyosarcomatous differentiation (malignant \u201cTriton\u201d tumors). Cancer. 1973;32(2):426\u2013439."},{"key":"i1543-2165-149-10-944-b03","series-title":"C R Assoc Anat","first-page":"279","article-title":"Formation de members surnumeraires","volume":"20","author":"Locatelli","year":"1925","unstructured":"Locatelli P. Formation de members surnumeraires. C R Assoc Anat. 1925;20:279\u2013282."},{"key":"i1543-2165-149-10-944-b04","series-title":"J Pathol","first-page":"151","article-title":"H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumors","volume":"252","author":"Lyskjaer","year":"2020","unstructured":"Lyskjaer I,\nLindsay D,\nTirabosco R, et al. H3K27me3 expression and methylation status in histological variants of malignant peripheral nerve sheath tumors. J Pathol. 2020;252:151\u2013164."},{"issue":"3","key":"i1543-2165-149-10-944-b05","series-title":"Mol Cell","first-page":"437","article-title":"PRC2.1 and PRC2.2 synergize to coordinate H3K27me3 trimethylation","volume":"76","author":"Healy","year":"2019","unstructured":"Healy E,\nMucha M,\nGlancy E, et al. PRC2.1 and PRC2.2 synergize to coordinate H3K27me3 trimethylation. Mol Cell. 2019;76(3):437\u2013452."},{"issue":"1","key":"i1543-2165-149-10-944-b06","series-title":"Mod Pathol","first-page":"4","article-title":"Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics","volume":"29","author":"Schaefer","year":"2016","unstructured":"Schaefer IM,\nFletcher CD,\nHornick JL. Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol. 2016;29(1):4\u201313."},{"issue":"11","key":"i1543-2165-149-10-944-b07","series-title":"Nat Genet","first-page":"1227","article-title":"PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors","volume":"46","author":"Lee","year":"2014","unstructured":"Lee W,\nTeckie S,\nWiesner T, et al. PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014;46(11):1227\u20131232."},{"issue":"10","key":"i1543-2165-149-10-944-b08","series-title":"Am J Surg Pathol","first-page":"1323","article-title":"Beyond \u201cTriton\u201d: malignant peripheral nerve sheath tumors with complete heterologous rhabdomyoblastic differentiation mimicking spindle cell rhabdomyosarcoma","volume":"43","author":"Hornick","year":"2019","unstructured":"Hornick JL,\nNielsen GP. Beyond \u201cTriton\u201d: malignant peripheral nerve sheath tumors with complete heterologous rhabdomyoblastic differentiation mimicking spindle cell rhabdomyosarcoma. Am J Surg Pathol. 2019;43(10):1323\u20131330."},{"key":"i1543-2165-149-10-944-b09","series-title":"Ann Diagn Pathol","first-page":"151735","article-title":"Loss of H3K27me3 occurs in a large subset of embryonal rhabdomyosarcomas: immunohistochemical and molecular analysis of 25 cases","volume":"52","author":"Tomassen","year":"2021","unstructured":"Tomassen T,\nKester LA,\nTops BB, et al. Loss of H3K27me3 occurs in a large subset of embryonal rhabdomyosarcomas: immunohistochemical and molecular analysis of 25 cases. Ann Diagn Pathol. 2021;52:151735."},{"issue":"6","key":"i1543-2165-149-10-944-b10","series-title":"Virchows Arch","first-page":"1233","article-title":"Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation","volume":"479","author":"Ito","year":"2021","unstructured":"Ito Y,\nKohashi K,\nEndo M, et al. Clinicopathological and prognostic significance of H3K27 methylation status in malignant peripheral nerve sheath tumor: correlation with skeletal muscle differentiation. Virchows Arch. 2021;479(6):1233\u20131244."},{"key":"i1543-2165-149-10-944-b11","series-title":"Ann Diagn Pathol","first-page":"151967","article-title":"Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): an immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors","volume":"59","author":"Thangaiah","year":"2022","unstructured":"Thangaiah JJ,\nWestling BE,\nRoden AC, et al. Loss of dimethylated H3K27 (H3K27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (MPNST): an immunohistochemical study of 137 cases, with emphasis on MPNST and melanocytic tumors. Ann Diagn Pathol. 2022;59:151967."},{"issue":"3","key":"i1543-2165-149-10-944-b12","series-title":"Histopathology","first-page":"385","article-title":"Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumors","volume":"70","author":"Asano","year":"2017","unstructured":"Asano N,\nYoshida A,\nIchikawa H, et al. Immunohistochemistry for trimethylated H3K27 in the diagnosis of malignant peripheral nerve sheath tumors. Histopathology. 2017;70(3):385\u2013393."},{"issue":"3","key":"i1543-2165-149-10-944-b13","series-title":"Mod Pathol","first-page":"435","article-title":"H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features","volume":"32","author":"Makise","year":"2019","unstructured":"Makise N,\nSekimizu M,\nKonishi E, et al. H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features. Mod Pathol. 2019;32(3):435\u2013445."},{"issue":"12","key":"i1543-2165-149-10-944-b14","series-title":"Mod Pathol","first-page":"1677","article-title":"Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions","volume":"30","author":"Le Guellec","year":"2017","unstructured":"Le Guellec S,\nMacagno N,\nVelasco V, et al. Loss of H3K27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod Pathol. 2017;30(12):1677\u20131687."},{"issue":"6","key":"i1543-2165-149-10-944-b15","series-title":"Mod Pathol","first-page":"582","article-title":"Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival","volume":"29","author":"Cleven","year":"2016","unstructured":"Cleven AHG,\nSannaa GAA,\nBriaire-de Bruijn I, et al. Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival. Mod Pathol. 2016;29(6):582\u2013590."},{"issue":"1","key":"i1543-2165-149-10-944-b16","series-title":"Brain Tumor Pathol","first-page":"23","article-title":"Reduced H3K27me3 levels in diffuse gliomas: association with 1p\/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors","volume":"38","author":"Kitahama","year":"2021","unstructured":"Kitahama K,\nIijima S,\nSumiishi A, et al. Reduced H3K27me3 levels in diffuse gliomas: association with 1p\/19q codeletion and difference from H3K27me3 loss in malignant peripheral nerve sheath tumors. Brain Tumor Pathol. 2021;38(1):23\u201329."},{"issue":"6","key":"i1543-2165-149-10-944-b17","series-title":"Acta Neuropathol","first-page":"955","article-title":"Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence","volume":"135","author":"Katz","year":"2018","unstructured":"Katz LM,\nHielscher T,\nLiechty B, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018;135(6):955\u2013963."},{"issue":"12","key":"i1543-2165-149-10-944-b18","series-title":"Mod Pathol","first-page":"1710","article-title":"Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors","volume":"30","author":"Pekmezci","year":"2017","unstructured":"Pekmezci M,\nCuevas-Ocampo AK,\nPerry A,\nHorvai AE. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol. 2017;30(12):1710\u20131719."},{"key":"i1543-2165-149-10-944-b19","series-title":"Am J Surg Pathol","first-page":"656","article-title":"The distinction between malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma: a critical reappraisal of the diagnostic utility of MDM2 and H3K27me3 status","volume":"42","author":"Makise","year":"2018","unstructured":"Makise N,\nSekimizu M,\nKubo T, et al. The distinction between malignant peripheral nerve sheath tumor and dedifferentiated liposarcoma: a critical reappraisal of the diagnostic utility of MDM2 and H3K27me3 status. Am J Surg Pathol. 2018;42:656\u2013664."},{"issue":"2","key":"i1543-2165-149-10-944-b20","series-title":"Histopathology","first-page":"321","article-title":"Radiation-associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation","volume":"78","author":"Panse","year":"2021","unstructured":"Panse G,\nMito JK,\nIngram DR, et al. Radiation-associated sarcomas other than malignant peripheral nerve sheath tumours demonstrate loss of histone H3K27 trimethylation. Histopathology. 2021;78(2):321\u2013326."},{"issue":"5","key":"i1543-2165-149-10-944-b21","series-title":"Mod Pathol","first-page":"640","article-title":"Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation","volume":"35","author":"Ishihara","year":"2022","unstructured":"Ishihara S,\nYamamoto H,\nIwasaki T, et al. Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation. Mod Pathol. 2022;35(5):640\u2013648."},{"issue":"6","key":"i1543-2165-149-10-944-b22","series-title":"Genes Chromosomes Cancer","first-page":"397","article-title":"High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis","volume":"50","author":"Paulson","year":"2011","unstructured":"Paulson V,\nChandler G,\nRakheja D, et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer. 2011;50(6):397\u2013408."},{"issue":"3","key":"i1543-2165-149-10-944-b23","series-title":"Clin Genet","first-page":"341","article-title":"Neurofibromatosis type 1 and malignancy in childhood","volume":"89","author":"Varan","year":"2016","unstructured":"Varan A,\n\u015een H,\nAyd\u0131n B,\nYal\u00e7in B,\nKutluk T,\nAky\u00fcz C. Neurofibromatosis type 1 and malignancy in childhood. Clin Genet. 2016;89(3):341\u2013345."},{"key":"i1543-2165-149-10-944-b24","series-title":"JCO Precis Oncol","first-page":"e2300597","article-title":"NF1-driven rhabdomyosarcoma phenotypes: a comparative clinical and molecular study of NF1-mutant rhabdomyosarcoma and NF1-associated malignant triton tumor","volume":"8","author":"de Traux de Wardin","year":"2024","unstructured":"de Traux de Wardin H,\nDermawan JK,\nVanoli F, et al. NF1-driven rhabdomyosarcoma phenotypes: a comparative clinical and molecular study of NF1-mutant rhabdomyosarcoma and NF1-associated malignant triton tumor. JCO Precis Oncol. 2024;8:e2300597."},{"issue":"3","key":"i1543-2165-149-10-944-b25","series-title":"Genes Chromosomes Cancer","first-page":"310","article-title":"Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes","volume":"33","author":"Bridge","year":"2002","unstructured":"Bridge JA,\nLiu J,\nQualman SJ, et al. Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. Genes Chromosomes Cancer. 2002;33(3):310\u2013321."},{"issue":"2","key":"i1543-2165-149-10-944-b26","series-title":"Cancer Discov","first-page":"216","article-title":"Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors","volume":"4","author":"Shern","year":"2014","unstructured":"Shern JF,\nChen L,\nChmielecki J, et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014;4(2):216\u2013231."},{"issue":"3\u20134","key":"i1543-2165-149-10-944-b27","series-title":"Crit Rev Oncog","first-page":"227","article-title":"Pediatric rhabdomyosarcoma","volume":"20","author":"Shern","year":"2015","unstructured":"Shern JF,\nYohe ME,\nKhan J. Pediatric rhabdomyosarcoma. Crit Rev Oncog. 2015;20(3\u20134):227\u2013243."},{"issue":"3","key":"i1543-2165-149-10-944-b28","series-title":"PLoS Genet","first-page":"e1005075","article-title":"Clonality and evolutionary history of rhabdomyosarcoma","volume":"11","author":"Chen","year":"2015","unstructured":"Chen L,\nShern JF,\nWei JS, et al. Clonality and evolutionary history of rhabdomyosarcoma. PLoS Genet. 2015;11(3):e1005075."},{"issue":"26","key":"i1543-2165-149-10-944-b29","series-title":"J Clin Oncol","first-page":"2859","article-title":"Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium","volume":"39","author":"Shern","year":"2021","unstructured":"Shern JF,\nSelfe J,\nIzquierdo E, et al. Genomic classification and clinical outcome in rhabdomyosarcoma: a report from an international consortium. J Clin Oncol. 2021;39(26):2859\u20132871."},{"issue":"4","key":"i1543-2165-149-10-944-b30","series-title":"Genes Chromosomes Cancer","first-page":"217","article-title":"Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma","volume":"15","author":"Iolascon","year":"1996","unstructured":"Iolascon A,\nFaienza MF,\nCoppola B, et al. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chromosomes Cancer. 1996;15(4):217\u2013222."},{"issue":"2","key":"i1543-2165-149-10-944-b31","series-title":"Cell","first-page":"265","article-title":"The regulation of INK4\/ARF in cancer and aging","volume":"127","author":"Kim","year":"2006","unstructured":"Kim WY,\nSharpless NE. The regulation of INK4\/ARF in cancer and aging. Cell. 2006;127(2):265\u2013275."},{"issue":"50","key":"i1543-2165-149-10-944-b32","series-title":"Proc Natl Acad Sci U S A","first-page":"20007","article-title":"Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma","volume":"104","author":"Beroukhim","year":"2007","unstructured":"Beroukhim R,\nGetz G,\nNghiemphu L, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007;104(50):20007\u201320012."},{"issue":"8","key":"i1543-2165-149-10-944-b33","series-title":"Blood","first-page":"4322","article-title":"Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis","volume":"111","author":"Balgobind","year":"2008","unstructured":"Balgobind BV,\nVan Vlierberghe P,\nvan den Ouweland AM, et al. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. Blood. 2008;111(8):4322\u20134328."},{"issue":"12","key":"i1543-2165-149-10-944-b34","series-title":"Neoplasia","first-page":"1362","article-title":"Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations","volume":"10","author":"Sangha","year":"2008","unstructured":"Sangha N,\nWu R,\nKuick R, et al. Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations. Neoplasia. 2008;10(12):1362\u20131372."},{"issue":"7521","key":"i1543-2165-149-10-944-b35","series-title":"Nature","first-page":"247","article-title":"PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies","volume":"514","author":"De Raedt","year":"2014","unstructured":"De Raedt T,\nBeert E,\nPasmant E, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514(7521):247\u2013251."},{"issue":"12","key":"i1543-2165-149-10-944-b36","series-title":"Arch Pathol Lab Med","first-page":"1878","article-title":"Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor)","volume":"130","author":"Stasik","year":"2006","unstructured":"Stasik CJ,\nTawfik O. Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch Pathol Lab Med. 2006;130(12):1878\u20131881."},{"issue":"1","key":"i1543-2165-149-10-944-b37","series-title":"Clin Epigenetics","first-page":"9","article-title":"Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population","volume":"16","author":"Patrizi","year":"2024","unstructured":"Patrizi S,\nMiele E,\nFalcone L, et al. Malignant peripheral nerve sheath tumor (MPNST) and MPNST-like entities are defined by a specific DNA methylation profile in pediatric and juvenile population. Clin Epigenetics. 2024;16(1):9."}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"link":[{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/10\/article-p944.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/149\/10\/944\/3541426\/i1543-2165-149-10-944.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/10\/article-p944.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aplm.kglmeridian.com\/downloadpdf\/journals\/arpa\/149\/10\/article-p944.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:13:53Z","timestamp":1770772433000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/149\/10\/article-p944.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":74,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.5858\/arpa.2024-0199-oa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"value":"1543-2165","type":"electronic"},{"value":"0003-9985","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}